Overview

This trial is active, not recruiting.

Condition insulin resistance
Treatments insulin
Phase phase 2
Sponsor Kaleida Health
Collaborator American Diabetes Association
Start date September 2008
End date September 2013
Trial size 60 participants
Trial identifier NCT01151605, 1934, 708CR13

Summary

This study will help us understand the possible beneficial effects of insulin in inflammation. Inflamamtion is considered to be the cause of atherosclerosis and heart disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose treatment
Arm
(Experimental)
20 obese subjects
insulin
insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
(Active Comparator)
20 lean subjects
insulin
insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
(Experimental)
20 type 2 diabetes
insulin
insulin to be infused at three different rates (2, 3.5 and 5 units/hour)

Primary Outcomes

Measure
The Suppression of Toll Like receptors by Insulin
time frame: 24 hours

Secondary Outcomes

Measure
TLR expression
time frame: 24 hours

Eligibility Criteria

Male or female participants from 20 years up to 65 years old.

INCLUSION CRITERIA Lean Group: 1. Age: 20 to 65 years of age inclusive 2. Sex: male or female 3. Normal fasting plasma glucose (65-100 mg/dl) 4. Normal BMI (20-25) Obese Group: 1. Age: 20 to 65 years of age inclusive 2. Sex: male or female 3. Normal fasting plasma glucose (65-100 mg/dl) 4. BMI> 30 DM Group: 1. Type 2 Diabetes Mellitus 2. Age: 20 to 65 years of age inclusive 3. Sex: male or female 4. BMI >30 5. Hba1c < 8% 6. If on statins, angiotensin converting enzyme inhibitor, angiotensin receptor blocker or low dose aspirin, should be on a stable dose for one month. EXCLUSION CRITERIA 1. Pregnancy 2. Congestive heart failure 3. Heart Rate <50 beats /minute 4. Sick Sinus Syndrome 5. Second or third degree heart block 6. Blood pressure <80 mm systolic or > 160/100 mmHg 7. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous three months 8. Hepatic disease (transaminase > 3 times normal) 9. Renal impairment (serum creatinine > 1.5) 10. History of drug or alcohol abuse within past one year 11. Participation in any other concurrent clinical trial 12. Potassium (K+) values <3.5 meq/l to > 5.5 meq/l) 13. Any other life-threatening, non-cardiac disease 14. Use of an investigational agent or therapeutic regimen within 30 days of study 15. Type 2 diabetics on thiazolidinediones and/ or insulin 16. Subjects on steroids, NSAIDS or antioxidants 17. Patients taking exenatide or sitaglipin or loop diuretics 18. Anemia (Hemoglobin level less than 12gm/dl in females and 13gm/dl in males) 19)Allergy to lidocaine

Additional Information

Official title The Suppression of Toll Like Receptors by Insulin
Principal investigator Paresh Dandona, MBBS
Description Obesity and type 2 diabetes are major health problems in the United States and the world. Both conditions are characterized by increased inflammation and oxidative stress and are associated with increased risk of cardiovascular disease. Our previous work shows that insulin exerts a prompt and powerful anti-inflammatory effect, on circulating blood cells and in plasma in healthy subjects and in critically ill patients. Toll like receptors (TLRs) recognize bacterial and viral products like endotoxin and viruses and are major determinants of the inflammatory response against foreign pathogens. In view of the recent data showing that TLRs recognize a range of molecules and proteins that are not of pathogenic source like saturated lipids and that TLRs are involved in the pathogenesis of atherosclerosis which leads to cardiovascular disease and insulin resistance which leads to type 2 diabetes (DM) we hypothesized that insulin infusion suppresses TLRs expression. Our preliminary data show that insulin infusion for 4 hours reduces the levels of many TLRs and thus might protect from inflammation induced conditions We therefore propose to investigate, in more detail, the effect of infusing different doses of insulin on TLRs mRNA and protein levels and its activity in obese and DM subjects over a longer infusion period and a larger number of subjects in circulating white blood cells and in fat tissue. Also we will be comparing the baseline levels of TLRs and TLRs related proteins as well as their modulation by insulin between normal, obese and DM subjects.
Trial information was received from ClinicalTrials.gov and was last updated in December 2012.
Information provided to ClinicalTrials.gov by Kaleida Health.